Targeting MDA-9 restrains head and neck tumor growth and eliminates therapy resistance
Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most-common type of cancer worldwide. However, the disease is often diagnosed at a late stage, once it has already spread to other organs, and the majority of patients receiving active treatment will develop resistance to chemotherapy within months, underscoring the need for more effective care strategies.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
